Literature DB >> 35533264

Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune Evasion.

Xutong Gong1,2, Rachel Karchin1,2,3.   

Abstract

Human leukocyte antigen (HLA) expression contributes to the activation of antitumor immunity through interactions with T-cell receptors. Pan-cancer HLA-mediated immunogenicity and immunoediting mechanisms have not been systematically studied previously. In a retrospective analysis of 33 tumor types from the Cancer Genome Atlas (TCGA), we characterized the differential expression of HLA class I and class II genes across various oncogenic pathways and immune subtypes. While HLA I genes were upregulated in all immunogenically hot tumors, HLA II genes were upregulated in an inflammatory immune subtype associated with best prognosis and were systematically downregulated in specific oncogenic pathways. A subset of immunogenically hot tumors which upregulated HLA class I but not class II genes exploited HLA-mediated escape strategies. Furthermore, with a machine learning model, we demonstrated that HLA gene expression data can be used to predict the immune subtypes of patients receiving immune checkpoint blockade and stratify patient survival. Interestingly, tumors with the highest immune infiltration did not have the best prognosis but showed significantly higher immune exhaustion. IMPLICATIONS: Taken together, we highlight the prognostic potential of HLA genes in immunotherapies and suggest that higher tumor immunogenicity mediated by HLA expression may sometimes lead to tumor escape under strong selective pressure. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35533264      PMCID: PMC9357147          DOI: 10.1158/1541-7786.MCR-21-0886

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  50 in total

Review 1.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

Review 2.  Developing neoantigen-targeted T cell-based treatments for solid tumors.

Authors:  Tori N Yamamoto; Rigel J Kishton; Nicholas P Restifo
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

Review 3.  HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.

Authors:  Elizabeth D Mellins; Lawrence J Stern
Journal:  Curr Opin Immunol       Date:  2013-12-08       Impact factor: 7.486

4.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

5.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Authors:  Jianfang Liu; Tara Lichtenberg; Katherine A Hoadley; Laila M Poisson; Alexander J Lazar; Andrew D Cherniack; Albert J Kovatich; Christopher C Benz; Douglas A Levine; Adrian V Lee; Larsson Omberg; Denise M Wolf; Craig D Shriver; Vesteinn Thorsson; Hai Hu
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

Review 6.  IFN inducibility of major histocompatibility antigens in tumors.

Authors:  Barbara Seliger; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 7.  Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.

Authors:  Rong En Tay; Emma K Richardson; Han Chong Toh
Journal:  Cancer Gene Ther       Date:  2020-05-27       Impact factor: 5.987

8.  Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.

Authors:  Denise M Wolf; Marc E Lenburg; Christina Yau; Aaron Boudreau; Laura J van 't Veer
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

Review 9.  Computational Prediction and Validation of Tumor-Associated Neoantigens.

Authors:  Vladimir Roudko; Benjamin Greenbaum; Nina Bhardwaj
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

10.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

Authors:  Nicholas McGranahan; Rachel Rosenthal; Crispin T Hiley; Andrew J Rowan; Thomas B K Watkins; Gareth A Wilson; Nicolai J Birkbak; Selvaraju Veeriah; Peter Van Loo; Javier Herrero; Charles Swanton
Journal:  Cell       Date:  2017-10-26       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.